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Abstract
Crohn’s disease (CD) is a complex disorder with variable age of onset, disease 
location and behavior. It is characterized by a transmural inflammation that may 
involve any portion of the gastrointestinal tract. Ileocolonoscopy with biopsy is 
established as the first-line investigation for suspected CD. However, small bowel 
involvement is more difficult to assess by conventional endoscopy. Therefore, 
radiological imaging should also be performed to complement ileocolonoscopy 
in all patients with suspected CD. Recently, video capsule endoscopy and device-
assisted enteroscopy have revolutionized the management of small bowel CD. In 
fact, video capsule endoscopy is a non-invasive test that provides the visualization 
of the entire small bowel mucosa, which can assist in the diagnosis of CD and assess 
the therapeutic response. On the other hand, device-assisted enteroscopy enables 
direct tissue sampling for histopathology confirmation when traditional endoscopy, 
video capsule endoscopy and cross-sectional imaging are inconclusive. Moreover, it 
allows therapeutic interventions such as balloon stricture dilation. In this chapter, 
we review the role of endoscopy in the diagnosis and management of patients with 
small bowel CD.
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1. Introduction
Crohn’s disease (CD) is an idiopathic inflammatory disorder with genetic, 
immunologic and environmental influences [1]. It is characterized by a transmural 
inflammation that may involve any portion of the luminal gastrointestinal tract, 
from the oral cavity to the perianal area. The diagnosis is based on the combination 
of clinical, biochemical, radiological, endoscopic and histological findings. CD is a 
chronic and progressive disease, marked by frequent relapses which usually require 
repeated investigations.
The most common symptoms of CD are diarrhea, abdominal pain and fatigue. 
However, clinical manifestations can be very heterogeneous, depending on the 
disease location and phenotype. Patients with CD often show laboratory evidence 
of inflammatory activity and anemia. In addition, fecal calprotectin and serum 
C-reactive protein are useful markers to detect and monitor inflammation. The 
endoscopic hallmark of CD is the patchy distribution of inflammation and mucosal 
biopsies usually show focal inflammation (rather than diffuse), crypt distortion 
and/or granulomas. Finally, cross-sectional imaging techniques provide informa-
tion about the bowel wall and extra-enteric soft tissues and, therefore, can better 
classify disease phenotype and behavior.
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Endoscopy has major implications not only for the diagnosis of CD but also 
for treatment and follow-up. Indeed, ileocolonoscopy and upper gastrointestinal 
endoscopy have well-established roles in assessing disease activity and therapeutic 
intervention. However, the small bowel is one of the most common areas affected in 
patients with CD, which is often inaccessible to conventional endoscopy. In addi-
tion, at the time of diagnosis, up to 30% of patients have only small bowel involve-
ment, especially in the young ones [2, 3]. The advent of video capsule endoscopy 
and both balloon-assisted and spiral enteroscopy is revolutionizing the manage-
ment of small bowel CD [4]. In fact, these techniques allowed direct visualiza-
tion of the entire small bowel which can assist in the diagnosis of CD. Moreover, 
device-assisted enteroscopy enables direct tissue sampling and allows therapeutic 
interventions. In this chapter, we aim to review the role of small bowel endoscopy in 
the management of patients with CD.
2. Diagnosis
2.1 Ileocolonoscopy
Colonoscopy with intubation of the terminal ileum and multiple biopsies is 
recommended as part of the initial evaluation of patients with suspected CD 
[5]. It has been reported a successful ileal intubation rate as high as % when 
the cecum is reached [6]. A minimum of two biopsies from five different sites, 
including the rectum and the ileum, should be obtained for a reliable diagnosis of 
CD. Samples are preferably obtained both from areas which are involved by the 
disease and from uninvolved areas. Mucosal changes suggestive of CD include 
discontinuous segments of edema, friability, ulcerations, fistulous orifices and 
stenosis (Figure 1). With respect to the histological exam, macroscopic and 
microscopic features include discontinuous chronic inflammation, with lym-
phocytes and plasma cells, focal crypt distortion and granulomas. Although the 
presence of granulomatous inflammation is helpful, it is not required for diagno-
sis and is seen in only 33% of patients with CD [7].
Ileocolonoscopy is also helpful for the detection of stenosis, allowing tissue 
sampling for pathological diagnosis of dysplasia and cancer. Complementary 
radiological techniques to rule out additional stenotic lesions are necessary when 
the lesion is impassable with the endoscope.
Attempts to quantify the distribution and severity of mucosal involvement of 
the colon and the ileum in patients with CD have led to the development of multiple 
endoscopic scoring systems. Endoscopic scores that have been validated for ileocolo-
noscopy include both the Crohn’s Disease Endoscopic Index of Severity (CDEIS) [8]  
Figure 1. 
Endoscopic appearance of Crohn’s disease - discontinuous segments of edema, friability, ulcerations (A) and 
stenosis (B and C).
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and the Simple Endoscopic Score for Crohn’s Disease (SES-CD) [9]. The CDEIS 
includes six endoscopic variables (presence of deep ulcers, superficial ulcers, nonul-
cerated stenosis, ulcerated stenosis, proportion of ulcerated surface and proportion 
of surface affected by disease), assessed in five bowel segments (terminal ileum, right 
colon, transverse, left colon and sigmoid, rectum) (Table 1). The CDEIS is com-
plicated to use and requires training and experience. Therefore, it is used mainly in 
clinical trials. On the other hand, the SES-CD has been helpful to translate endoscopic 
activity into clinically meaningful and is easier to use and understand. The SES-CD 
includes four variables, each considered in five bowel segments (ulcer size, extent of 

























Total 1 + 2 + 3 + 4 Total A
Number of segments totally or partially explored n
Total A divided by n Total B
Quote 3 if ulcerated stenosis anywhere C
Quote 3 if nonulcerated stenosis anywhere D
Total B + C + D CDEIS
Table 1. 
Crohn’s disease endoscopic index of severity (CDEIS). CDEIS includes deep ulceration (no = 0, yes = 12), 
superficial ulceration (no = 0, yes = 6), surface involved by disease (0–10), ulcerated surface (0–10), and 
ulcerated or non-ulcerated stenosis (no = 0, yes = 3), each considered in five ileocolonic segments. Severe disease: 
CDEIS ≥12, moderate disease: CDEIS = 9–12, mild disease: CDEIS = 3–9, remission: CDEIS <3.
Variable 0 1 2 3




Very large ulcers 
(>2 cm)
Ulcerated surface None <10% 10–30% >30%
Affected surface None <50% 50–75% >75%
Presence of 
narrowing




Simple endoscopic score for Crohn’s disease (SES-CD). SES-CD = sum of all variables of each explored segment 
(ileum, right colon, transverse colon, left colon and rectum). Severe disease: SES-CD ≥16, moderate disease: 
SES-CD = 7–15, mild disease: SES-CD = 3–6, inactive disease: SES-CD <3.
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It is important to note that up to 25% of patients have isolated proximal small 
bowel disease beyond the reach of even complete ileocolonoscopy [10]. Therefore, 
radiological imaging should be performed in all patients with suspected CD to 
complement ileocolonoscopy.
2.2 Upper gastrointestinal endoscopy
The presence of CD of the upper gastrointestinal tract, including the duodenum, 
is uncommon in adults, with most studies showing a prevalence range of 0.3–5% 
[11]. Moreover, the majority of patients are asymptomatic at the time of evaluation 
[12]. However, it is important to note that CD in the proximal gastrointestinal tract 
is associated with a worse prognosis and there is usually a low threshold to initiate 
therapy with anti-tumor necrosis factor (TNF).
CD involving the upper gastrointestinal tract is almost invariably accompanied 
by small or large bowel involvement [13]. Esophagogastroduodenoscopy is recom-
mended in patients with upper gastrointestinal signs and symptoms, being still 
debated whether asymptomatic adult CD patients should routinely undergo upper 
endoscopy [6]. In fact, esophagogastroduodenoscopy may support the diagnosis 
when it is difficult to obtain a histological diagnosis of CD. In addition, a more 
recent prospective registry reported a higher prevalence of upper gastrointestinal 
involvement in asymptomatic patients than initially expected, suggesting a place for 
a standard gastroscopy to correctly evaluate disease extent at diagnosis [12].
Endoscopic features suggestive of upper gastrointestinal involvement include 
mucosal nodularity, aphthous ulcers, superficial erosions, antral thickening and 
duodenal strictures [1]. Histologic changes consistent with CD are granulomatous 
inflammation, focally enhanced gastritis and focal cryptitis of the duodenum.
In the presence of upper tract stenosis, balloon dilatation is recommended as 
first-line therapy, followed by proton pump inhibitors as second-line and steroids/
thiopurines/surgery as third-line [14]. Currently, there is no credible evidence to 
support the best modality to assess response to treatment of upper gastrointestinal 
CD, therefore it must be primarily monitored by the reference standard endoscopy.
2.3 Video capsule endoscopy
Video capsule endoscopy is a method of endoluminal examination of the small 
bowel using a wireless capsule-shaped tool which is swallowed and then propelled 
through the gastrointestinal tract by gut motility [15]. Preparations for a video 
capsule endoscopy study usually include 8–12 hours’ fasting and some method of 
bowel cleansing (e.g. polyethylene glycol preparation). During the battery life of 
the capsule, images of the small bowel are recorded and reformatted into a continu-
ous video file. After 8–10 hours, the antenna and storage unit are removed and the 
images transferred to a computer with specially adapted software. Images are then 
downloaded, processed and examined by a trained gastroenterologist (Figure 2).
In addition to the small-bowel capsule, there are currently two more: the esopha-
geal and the colon capsules [16]. The esophageal capsule is the same size as the 
small bowel capsule, but has lenses on both ends of the ‘pill.’ The capsule battery life 
is only 20 minutes (vs. 8–12 hours for small-bowel capsules), cameras are located on 
both ends of the capsule and take 18 frames per second (vs. 2–3 frames per second 
for small-bowel capsules). On the other hand, the second-generation colon capsule 
endoscope is equipped with two high-resolution cameras providing a viewing 
angle of 172° in front and back, senses the moving speed of the capsule endoscope 
and captures 4 to 35 images per second [17]. This capsule was primarily utilized 
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in screening for colonic neoplasia, particularly in situations such as incomplete 
colonoscopy. However, it can play a key role in the diagnosis and evaluation of CD 
extent, severity and prognosis, with treatment modifications based on data from 
capsule examination.
Video capsule endoscopy is a useful adjunct in the diagnosis of patients with 
small bowel CD since it allows for direct visualization of the mucosa of the entire 
small intestine. It is able to identify mucosal lesions compatible with CD in patients 
in whom conventional endoscopic and small bowel radiographic imaging modali-
ties have been nondiagnostic, especially in the proximal small bowel [18]. Several 
meta-analyses have examined the diagnostic yield of video capsule endoscopy in 
the evaluation of patients with suspected CD and showed that it is superior to small 
bowel barium studies, computed tomography enterography and ileocolonoscopy, 
with an incremental yield of diagnosis of 32%, 47% and 22%, respectively [19]. 
Moreover, video capsule endoscopy has a negative predictive value of 96%, essen-
tially ruling out small bowel CD [20]. On the other hand, a study examining the 
sensitivity and specificity of different endoscopic and radiologic exams showed that 
the specificity of video capsule endoscopy was significantly lower than the other 
tests [21]. In fact, detected lesions are nonspecific and cannot be distinguished from 
those seen in patients treated by nonsteroidal anti-inflammatory drugs (NSAIDs). 
Therefore, video capsule endoscopy should be reserved for cases in which ileocolo-
noscopy plus small bowel radiography is not diagnostic, but there is a high rate of 
CD suspicion.
Although there are no validated diagnostic criteria for the diagnosis of CD, the 
presence of more than three small bowel ulcerations, in the absence of NSAIDs 
ingestion for at least 1 month before the exam, constitutes the most commonly used 
diagnostic criterion in practice [22]. In addition, there are currently two validated 
indexes available, the Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI) 
[23] and the Lewis Score [24], which assess the disease location and activity of 
small bowel involvement. The CECDAI was validated in a multicenter prospective 
study of patients with isolated small bowel CD and evaluates the following three 
endoscopic parameters: inflammation, extent of disease and strictures for both 
the proximal and the distal segments of the small bowel, based on the transit time 
of the capsule (Table 3). The Lewis score is another scoring system based on the 
evaluation of three endoscopic parameters: villous appearance, ulcers and strictures 
(Table 4). The small bowel is divided into three equal parts and, for each tertile, 
a subscore is determined. The Lewis Score is the sum of the worst affected tertile 
plus the stenosis score. Both the scoring systems are incorporated into the software 
platform of the capsules and assists in the quantification of small bowel inflamma-
tory burden and diagnosis of CD.
Figure 2. 
Video capsule endoscopy images showing mucosal inflammation and ulcerations consistent with a diagnosis of 
Crohn’s disease.
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Video capsule endoscopy may also identify a site for directed visualization with 
other endoscopic techniques. In fact, it can be complementary to device-assisted 
endoscopy since findings may help direct the most effective route of intubation 
(oral versus anal), in order to obtain a histopathological diagnosis or therapeutic 
intervention.
In addition, video capsule endoscopy allows detection of subtle small bowel 
lesions, which may affect the therapeutic management. Because of the high sensi-
tivity of video capsule endoscopy, it has a potential role in the assessment of muco-
sal healing after drug therapy and can be used in the follow-up of treated patients. 
In fact, video capsule endoscopy has a significant impact on disease management 
and is associated with earlier escalation of therapy. In the largest retrospective series 
of patients with established CD that were evaluated with video capsule endoscopy, a 
change in management was suggested in 40–52% of individuals [25, 26].
The main advantage of video capsule endoscopy is the ability to visualize all of 
the small bowel with minimal discomfort for the patient. However, it lacks thera-
peutic capabilities and there is some risk of impaction due to possible strictures. 
Parameter Score and descriptor
A - Inflammation 0 - None
1 – Mild to moderate (edema, hyperemia or denudation)
2 – Severe (edema, hyperemia or denudation)
3 – Bleeding, exudate, erosion aphthae, ulcers <0.5 cm
4 – Pseudopolyp, ulcers 0.5-2 cm
5 – Ulcers >2 cm
B – Extent of disease 0 – None
1 – Sigle segment (focal disease)
2–2-3 segments (patchy disease)
3 - >3 segments (diffuse disease)
C - Stricture 0 – None
1 – Single-passed
2 – Multiple-passed
3 – Obstruction (non-passage)
Table 3. 
Capsule endoscopy Crohn’s disease activity index (CECDAI). CECDAI = proximal segment (A x B + C) + 
distal segment (A x B+C). Clinical or endoscopic remission: CEDAI <4.
Parameter Descriptor or 
number
Longitudinal extent Descriptor














15- Whole tertile (>50%)
9- < ¼










Lewis score. Score total = worst-affected tertile villous appearance and ulcers plus stenosis score. Clinically 
insignificant inflammation: Lewis score <135, mild inflammation: Lewis score = 135–790, moderate to severe 
inflammation: Lewis score >790.
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The capsule retention rate in patients with suspected CD is 1.5–5.4% but can reach 
13% in those with established CD, particularly if there are known intestinal stenosis 
[27, 28]. Therefore, those with obstructive symptoms or established CD of the small 
bowel should always have small bowel imaging and/or patency capsule evaluation 
before video capsule endoscopy to decrease the risk of capsule retention. Video 
capsule endoscopy is considered safe if the patency capsule is excreted before 
30 hours, an intact capsule is excreted after 30 hours or passage to the colon of an 
intact patency capsule has been radiologically confirmed. Another disadvantage 
of video capsule endoscopy is that the quality of images is not comparable to the 
view achieved at conventional endoscopy with gas insufflation. In addition, it has 
been reported that the caecum is not reached in 8–40% of video capsule endoscopy 
studies [22, 29]. Finally, the most serious complication reported with video capsule 
endoscopy is perforation, which has been exceedingly rare [30].
2.4 Device-assisted endoscopy
Device-assisted endoscopy is a generic term for any endoscopic technique that 
includes assisted progression (i.e. balloons and overtubes) and comprises double-
balloon enteroscopy, single-balloon enteroscopy and spiral enteroscopy [31]. 
Device-assisted endoscopy allows direct mucosal visualization of the entire small 
bowel as well as tissue sampling and therapeutic intervention (Figure 3). However, 
it is technically challenging and may require a bi-directional approach, deep seda-
tion or general anesthesia.
Double-balloon enteroscopy was introduced in 2001 as the first method for 
device-assisted enteroscopy [32]. It allows deep intubation of the small bowel by 
pleating the bowel onto a long and flexible endoscope fitted with an overtube. 
The endoscope and the accompanying overtube have balloons at their distal end. 
By intermittent inflation and deflation of these two balloons, combined with 
instrument insertion and retraction, large portions of the small bowel can be 
visualized directly. Oral and anal routes are used to achieve a complete small bowel 
examination.
Single-balloon enteroscopy is able to achieve a complete examination of the 
small bowel using principles similar to double-balloon enteroscopy. However, in 
contrast to double-balloon enteroscopy, this exam has only one balloon at the distal 
end of the overtube, which simplifies the preparation of the scope before starting 
the procedure. Single-balloon enteroscopy uses scope tip angulation and suction 
instead of balloon inflation to maintain a stable position while advancing the 
overtube.
Spiral enteroscopy is based on a completely different concept, by pleating of the 
bowel on the instrumentation shaft by active rotation instead of applying pushing 
force. The distal end of the overtube harbors a flexible spiral thread for pleating 
the small intestine over the overtube. By manually rotating the overtube, the spiral 
engages the small bowel which is thus pleated onto or unpleated from the overtube, 
respectively, depending on the direction of the spiral rotation. Spiral assisted 
endoscopy has been approved for both anterograde and retrograde enteroscopy.
The Motorized Spiral Enteroscope is a new technology with an incorporated 
user-controlled motor contained in the handle of the endoscope [33]. This would 
offer the possibility to accelerate the procedure, facilitate insertion and simplify 
the technique with a single operator. Recently, Beyna et al. demonstrated that the 
Motorized Spiral Enteroscope is effective for diagnostic and therapeutic antegrade 
enteroscopy and may compare favorably with traditional methods of deep enteros-
copy in ease of use and procedural duration [34].
Endoscopy in Small Bowel Diseases
8
Device-assisted endoscopy is not part of routine diagnostic testing in patients 
with suspected CD and should not be the first-line procedure in the evaluation 
of small bowel [1]. However, it may provide additional information when it 
is required biopsy of small bowel tissue to histological corroboration. Indeed, 
compared with video capsule endoscopy and small bowel imaging techniques, the 
advantages of device-assisted endoscopy include the evaluation of atypical lesions, 
the ability to obtain biopsies for histopathology and the potential for therapeutic 
intervention.
Device-assisted endoscopy studies in individuals with suspected CD have not 
included large numbers of patients but report a diagnostic yield as high as 80% 
[35]. In fact, device-assisted endoscopy is more sensitive in detecting lesions 
in patients with suspected CD than multiple radiographic imaging techniques. 
Nevertheless, because of the invasive and potentially time-consuming nature of 
the exam, it should be reserved for patients with high clinical suspicion of CD 
despite negative conventional studies (including ileocolonoscopy, video capsule 
endoscopy and radiographic imaging), particularly if endoscopic and histologic 
finding would alter disease management or potential therapeutic intervention 
is required [36]. In a prospective trial, positive findings at device-assisted enter-
oscopy led to a step-up of medical therapy in 74% of patients, leading to clinical 
remission in 88% [37]. In addition, device-assisted endoscopy may be preferable 
to video capsule endoscopy if there is a clinical suspicion of obstruction because 
it may allow therapeutic intervention and be safer, simply by avoiding capsule 
retention.
In patients with established CD, device-assisted endoscopy is indicated when 
endoscopic visualization and biopsies are necessary from areas of the small bowel 
inaccessible to conventional endoscopy [1]. Usually, previous video capsule endos-
copy provides information on the optimal route of approach (oral or rectal) and 
lesion location. Adhesions may limit examination by device-assisted endoscopy 
and, in these circumstances, double-balloon enteroscopy may be preferred to 
single-balloon enteroscopy. In addition, device-assisted endoscopy has the capacity 
for endoscopic therapy, including dilation of small bowel strictures, removal of 
impacted capsules and treatment of bleeding lesions (vide infra).
Overall, diagnostic device-assisted endoscopy is safe, with few reports of 
complications (<1%) [38]. However, there appears to be an increased risk of 
complications in the case of active CD or previous intestinal surgery. The risk  
of perforation is 0.12% without therapeutic intervention and 1.74% with thera-
peutic intervention, the majority of which occurred after stricture dilatation 
[39]. Bleeding occurs in approximately 2.5%. In addition, device-assisted endos-
copy involves risks related to sedation, in contrast to video capsule endoscopy 
where no sedation is required.
Figure 3. 
Device-assisted endoscopy images showing mucosal inflammation and ulcerations consistent with a diagnosis of 
Crohn’s disease.
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3. Treatment
3.1 Treatment of intestinal strictures
Strictures in CD develop during the course of the disease or as the presenting 
feature and are believed to result from partial healing and localized fibrosis. In 
addition, almost one-third of CD patients develop an anastomotic stricture after 
ileocecal resection/right hemicolectomy [40]. As a progressive disease, anastomotic 
strictures will be more likely over time.
Immunomodulators and biologic agents have been widely used for the treatment 
of CD, however endoscopic dilatation is a preferred technique for the management 
of symptomatic and mild to moderate stenosing disease [41]. Indeed, medical 
therapy for stricture management is limited due to fibrotic nature. Endoscopic 
dilatation may prevent or delay the need for surgical resection or strictureplasty. 
Moreover, endoscopic balloon dilation should be performed to access the mucosa 
proximal to strictures and evaluate disease activity, that otherwise may be missed 
if we only relied on symptoms or biochemical markers [42]. Thus, it can provide 
adequate endoscopic therapy and adjust or optimize medical therapy.
Endoscopic balloon dilation may be used in Crohn’s strictures of the gastric 
outlet, duodenum, colon, ileocolonic anastomosis and of the small bowel, if acces-
sible [43]. It is performed using a through-the-scope balloon catheter, which is a 
simple and safe procedure (Figure 4). The dilation procedure is performed with 
monitoring of the pressure of the inflated balloon using a dilator with or without 
X-ray guidance. When performing endoscopic balloon dilation, forcible dilation 
to achieve a larger dilation diameter or pressure is not recommended, as it could 
lead to intestinal perforation. The length of the balloons for inflation is about 5 cm; 
therefore, stenoses longer than 5 cm are considered unsuitable for endoscopic 
balloon dilation. Moreover, intestinal strictures with deep ulcers and fistulous 
complications are contraindications for endoscopic dilatation. In case of long or 
inflammatory strictures, balloon dilation may significantly increase the risk of 
perforation [44]. Hence, inflammatory and ulcerative strictures should be primarily 
treated with medical therapy.
Over the last years, there is increasing evidence for endoscopic balloon dilation 
as a safe and minimally invasive effective method for the treatment of strictur-
ing disease. In a retrospective single tertiary center study, Lopes et al. evaluated 
the long-term efficacy and safety of endoscopic balloon dilation in ileocolonic 
Figure 4. 
A segment of short stenosis is delineated using injection of contrast via a catheter (A).  A guide wire is inserted 
through the stenosis and a balloon is then advanced over the wire and carefully inflated (B).
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strictures. The authors reported a technical success rate of 97.7% to anastomotic 
strictures and similar to non-anastomotic strictures (100%) without major adverse 
events (major bleeding and perforation) [40]. Endoscopic dilatation using balloon-
assisted enteroscopy for small bowel strictures is almost the same as for ileocolonic 
strictures in terms of procedure and technique. However, there are some technical 
difficulties. In fact, it is not easy to stabilize the tip of the scope and to maintain a 
good visual field because of the limited space available, severe angulation, motility 
and adhesion in the small intestine. Nevertheless, the reported technical success 
rate is over 85% with a perforation rate of 1% [45, 46].
A key concern of endoscopic dilatation is the long-term outcome. Indeed, a 
recent study showed that 63% of patients with anastomotic strictures and 41% 
of those with non-anastomotic strictures required additional dilation over a 4.4-
year period [40]. However, Sunada et al. reported that the surgery-free rate in 321 
patients with CD who underwent endoscopic dilatation for small intestinal stric-
tures was 87% and 78% at 1 and 3 years, respectively [47]. Similarly, a systematic 
review assessed the role of device-assisted enteroscopy in 581 small bowel dilata-
tions, showing an 80% long-term success rate without the need for surgery during 
follow-up (2.5 years per patient) [48].
In conclusion, endoscopic balloon dilation is a feasible, simple, effective and safe 
procedure and an appropriate option for either delaying or preventing surgery, with 
the possibility of being repeated as needed.
To have a persistent effect over time and avoid the high risk of recurrence, a 
self-expanding metallic stent has been proposed [49]. Stenting appeared to be an 
effective technique in treating symptomatic CD intestinal strictures, however the 
procedure was associated with a high rate of spontaneous migrations and compli-
cations. More recently, an anti-migration, removable and shaped self-expandable 
metal stent is available. Attar et al. performed a real-life study to describe short-
and long-term results of the removable anti-migration stent [50]. The authors 
showed that it was safe and effective in about half of patients and had an extremely 
low migration rate, with no perforation reported. In addition, the high success rate 
was close to that obtained with endoscopic balloon dilation, but without compli-
cations. Taking this into account, the placement of a transient metallic stent is a 
new minimally invasive alternative to the management of refractory anastomotic 
stricture of less than 5 cm, before considering a new surgery. The use of biodegrad-
able instead of metal stents was recently evaluated in intestinal and colonic CD 
strictures. Although it was technically feasible, premature stent failure occurred 
in all of the patients, as well as side effects such as mucosal overgrowth and stent 
collapse [51].
3.2 Removal of impacted capsules
One problem of video capsule endoscopy in patients with suspected or known 
CD is the risk of impaction due to previously undiagnosed stenoses. One effort to 
overcome this difficulty was the development of the patency capsule. However, the 
successful passage of the patency capsule does not absolutely guarantee that intes-
tinal obstruction will not occur during the passage of the video capsule. Similarly, 
some stenoses may not be detected by prior radiographic methods. Therefore, 
capsule impaction can occur.
A retained capsule, in general, does not cause obstruction. In fact, the capsule 
can remain in the small bowel for several months without causing symptoms. Thus, 
unless malignancy is strongly suspected, conservative or pharmaceutical interven-
tion, namely with corticosteroids, are justified therapeutic options in the majority 
of cases [52].
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When patients develop obstructive symptoms, they may have to undergo 
device-assisted enteroscopy or surgery. Push-and-pull enteroscopy using the 
double-balloon technique has proven to be extremely effective (90–100% of cases) 
and is considered the method of choice [53]. Surgery is an alternative procedure 
for removing impacted capsules, especially in those cases in which investigations 
unequivocally suggest the presence of neoplastic disease. The surgical interven-
tion allows the removal of both the capsule and the pathology that caused capsule 
retention. In addition, intra-operative enteroscopy can be a useful tool to establish 
intra-luminal pathology like ulceration as a cause of retained endoscopic capsule.
Besides some cases of acute intestinal obstruction, there are only a few more 
complications reported in the literature due to a retained capsule. In fact, bowel 
perforation and capsule disintegration have already been reported, but only in case 
reports [54, 55].
3.3 Treatment of bleeding lesions
CD may be associated with mild gastrointestinal bleeding while major hemor-
rhage is a rare complication. In addition, a definitive bleeding site is not identified 
in most patients. In fact, hemorrhage is frequently attributed to diffuse areas of 
active inflammation [56]. The majority of bleeds originate from the ileum and colon 
and only a small number of episodes have been attributed to a jejunal or upper 
gastrointestinal source.
Initial management of major hemorrhage should always include primary 
resuscitation, as in any individual with a significant gastrointestinal bleed [57]. 
Once a patient is stabilized, diagnostic maneuvers are of primary importance. The 
site of bleeding can be identified by endoscopy, angiography or labeled red blood 
cell scans. However, clinicians should be aware that identifying a precise source of 
bleeding is difficult and salvage surgery may be necessary.
In the context of CD, urgent device-assisted enteroscopy for large-volume 
bleeding should be performed via the retrograde route, given the propensity of 
these conditions to involve the distal small bowel [52]. When it is identified, the 
source of bleeding is more commonly described as a deep ulcer eroding into a blood 
vessel and therapy may be attempted [56]. Endoscopy therapy includes thermoco-
agulation alone or a combination of epinephrine injection and bipolar coagulation 
[58]. Application of hemoclips may be compromised in the presence of inflamed 
and friable mucosa. On rare occasions, a large pseudopolyp in the ileum or colon 
has been identified as the source of bleeding; polypectomy should be performed 
in these cases. Although endoscopic therapy can stop acute bleeding, it does not 
promote mucosal healing and therefore cannot prevent rebleeding. In fact, the 
risk of rebleeding associated with endoscopic hemostasis is about 50% [56]. Thus, 
therapies that can induce and maintain mucosal healing are necessary to prevent 
rebleeding, such as anti-TNF agents.
Intraoperative enteroscopy may be the most reliable method to achieve a com-
plete small bowel evaluation. It involves evaluation of the small bowel at laparotomy 
and may be performed orally, rectally or via an enterotomy. Upper endoscopes, 
colonoscopes, push enteroscopes and balloon-assisted scopes have all been used. 
Although it is highly invasive and associated with major complications, it may help 
in the identification of the bleeding source and in planning the optimal therapeutic 
intervention [59].
When CD is complicated by obscure bleeding, video capsule endoscopy and 
device-assisted endoscopy may identify and treat the bleeding source beyond the 
reach of standard endoscopes [1]. In fact, video capsule endoscopy has a funda-
mental role in diagnosing obscure gastrointestinal bleeding in patients with CD. It 
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has been found to be superior to push enteroscopy and small bowel radiography. 
Video capsule endoscopy should be performed immediately after a negative upper 
and lower endoscopy as a screening method. The results of video capsule endoscopy 
should guide the use of device-assisted endoscopy, which aims at both the confir-
mation and treatment of the detected lesions.
3.4 Intralesional injection
Although local injection of immunomodulatory drugs like corticosteroids and 
infliximab CD stricture may look like an attractive therapeutic strategy [60], the 
available evidence is inconsistent. Some studies have shown benefit of intralesional 
injection of triamcinolone [61] and infliximab [62] at the time of balloon dilatation 
of CD. On the other hand, East et al. compared local quadrantic injection of tri-
amcinolone after endoscopic balloon dilatation of Crohn’s ileocolonic anastomotic 
strictures vs. saline placebo and showed that a single treatment of intrastricture 
triamcinolone injection did not reduce the time to redilatation [63]. Moreover, there 
was a trend toward a worse outcome. Similarly, Atreja et al. reported that intral-
esional steroid or biologics injection did not decrease the need for re-intervention 
or surgery for either primary or anastomotic strictures [64]. Until now, there is no 
strong evidence supporting the injection of drugs at the site of strictures and larger 
series are needed to evaluate the real effectiveness of these techniques in the treat-
ment of patients with obstructive strictures.
4. Postoperative recurrence
In the natural history of CD, intestinal resection is unavoidable in a significant 
proportion of patients. The majority of individuals will develop disease recurrence 
at or above the anastomosis, which usually occurs within a few weeks to months 
after ileocolonic resection [65].
Diagnosis of postoperative recurrence is based on clinical symptoms, serum and 
fecal markers, radiological and endoscopic findings. Nevertheless, ileocolonoscopy 
remains the gold standard, by defining the presence and severity of morphological 
recurrence [41]. It is recommended within the first 6 to 12 months after surgery, 
when treatment decisions may be affected. In fact, endoscopic recurrence usu-
ally precedes clinical recurrence and severe endoscopic recurrence predicts a 
poor prognosis. Rutgeerts et al. developed an endoscopic scoring system to assess 
postoperative recurrence in patients having ileocolonic resection [66]. The patients 
were stratified into five groups according to the endoscopic severity (Table 5). An 
Rutgeerts´ 
score
Endoscopic description of findings
i0 No lesions
i1 ≤5 aphthous ulcers
i2 >5 aphthous ulcers with normal intervening mucosa, skip areas of larger lesions or lesions 
confined to ileocolonic anastomosis
i3 Diffuse aphthous ileitis with diffusely inflamed mucosa
i4 Diffuse inflammation with large ulcers, nodules and/or narrowing
Table 5. 
Rutgeerts´ score. Postoperative recurrence: Rutgeerts score = i2-i4.
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endoscopic score of i0 or i1 correlated with a low risk of endoscopic progression 
and had clinical recurrence rates of less than 10% over 10 years. An endoscopic 
score of i2 or above suggests mucosal inflammation and should prompt considered 
treatment escalation [14]. However, it is important to note that the i2 category, 
including aphthous lesions in the terminal ileum as well as ileocolonic anastomosis 
lesions, had a heterogeneous recurrence risk. Therefore, a modified Rutgeerts’ 
score has recently emerged in which i2 is subdivided into i2a for lesions confined 
to the ileocolonic anastomosis, including anastomotic stenosis, and i2b for more 
than 5 aphthous ulcers or larger lesions, with normal mucosa in between, in the 
neoterminal ileum, with or without anastomotic lesions [67]. With this modified 
score, stenosis and/or ulceration of the anastomosis, which might simply be related 
to ischemia or staples, do not define recurrent disease and have no prognostic or 
therapeutic implications [68]. Thus, possible confounding factors for recurrent 
disease are overcome with this score.
Video capsule endoscopy can also be used to assess postoperative recurrence of 
CD and should be considered if ileocolonoscopy is contraindicated or unsuccess-
ful. Video capsule endoscopy may identify lesions in the small bowel that have not 
been detected by ileocolonoscopy after ileocolic resection. An important advantage 
of capsule endoscopy is the ability to detect proximal small bowel recurrence. 
However, patency capsule evaluation is recommended before capsule endoscopy to 
minimize the risk of retention.
5. Small bowel malignancy
Patients with CD are at an increased risk of developing malignancy, which is 
more frequent in the CD-affected colon. However, those with small bowel involve-
ment may also develop cancer, which can be difficult to diagnose. In fact, compared 
with an age-matched population, patients with CD have an 18-fold increased 
incidence of small bowel malignancy and only a minority are detected at an early 
stage [69]. Adenocarcinoma is the most common form of all small bowel cancer. 
Prognosis of small bowel adenocarcinoma is poor and the mortality at 1 and 2 years 
ranges from 30–60% dependent on the stage of cancer [70].
Early detection of small bowel carcinoma remains a problem. Radiological 
imaging and video capsule endoscopy could potentially detect malignancies at an 
early stage. However, differentiation between inflammatory stenosis and cancer is 
difficult. In these cases, device-assisted enteroscopy should be performed to direct 
visualization and tissue sampling. Furthermore, these procedures are not routinely 
used for screening asymptomatic individuals. Therefore, every patient who has a 
change of symptoms should perform further exams as this might be an indicator of 
malignancy [69]. Moreover, most of the small bowel carcinoma in CD is located in 
strictures, so the endoscopist should have a low threshold for taking biopsies before 
endoscopic balloon dilatation [71].
6. Conclusions
Endoscopy has major implications for diagnosis, classification, therapeutic 
decision and prognosis of CD. Ileocolonoscopy with biopsy is the first-line exam 
for suspected CD. However, the small bowel is one of the most affected areas by 
inflammation, which may skip the terminal ileum and not be detected by ileoscopy. 
In fact, small intestine involvement is more difficult to assess by conventional 
endoscopy. In addition, radiological examinations, including both magnetic 
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resonance imaging and computed tomography, may not detect disease of the small 
bowel, especially in mild lesions.
Until a decade ago, mucosal visualization of the small intestine was limited 
to the reach of the push enteroscope. The advent of video capsule endoscopy and 
device-assisted endoscopy is revolutionizing small bowel CD diagnosis and treat-
ment. In fact, these techniques allowed direct visualization of the entire small intes-
tine, which would alter patient management, especially in those with inconclusive 
results from conventional studies. Device-assisted endoscopy has also the ability to 
obtain biopsies for histopathology and the potential for therapeutic intervention. 
Finally, video capsule endoscopy and device-assisted endoscopy play an important 
role in assessing response to therapy.
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